A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
There is presently no approved single treatment for dual alcohol and nicotine dependencies. This pilot study investigated baclofen effects in alcoholic smokers. This was a preliminary double-blind placebo-controlled randomized clinical study with 30 alcoholic smokers randomized to baclofen at 80 mg/day or placebo. A subgroup (n = 18) participated in an alcohol cue-reactivity experiment. Baclofen, compared with placebo, significantly decreased the percent days of abstinence from alcohol-tobacco co-use (p = 0.004). Alcohol dependence severity moderated baclofen effects, with the higher severity group having the greater baclofen response (p < 0.001). Although the percent days of alcohol-tobacco co-use declined in both groups, this decline was greater after placebo than baclofen (p < 0.001). Secondary analyses on alcohol or tobacco use alone suggested that the increase in percent days of co-abstinence was driven by the medication differences on heavy drinking days and on percent days smoking. In the cue-reactivity substudy, baclofen slightly decreased alcohol urge (p = 0.058) and significantly reduced salivation (p = 0.001), but these effects were not related to cue type. This study provides preliminary evidence suggesting a possible role of baclofen in the treatment of alcoholic smokers. However, the mixed results and the small sample require larger confirmatory studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598 · cited 2×
“Additionally, alcohol and nicotine dependence severity were assessed by the Alcohol Dependence Scale (ADS), on which scores range from 0 to 47 (Skinner and Allen 1982) and the Fagerström Test for Nicotine Dependence (FTND), on which scores range from 0 to 10 (Fagerstrom and Schneider 1989).”
Grant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1107 · Cited by 1,262 · cited 3×
“Spontaneous smoking cessation is infrequent among alcoholic individuals (Falk et al. 2006; Hintz and Mann 2007) and up to 75 % of alcoholic smokers would require treatment for both dependencies (Grant et al. 2004).”
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188 · cited 5×
“Specifically, after controlling for baseline scores and race, BACL significantly reduced the QSU-B score (BACL, 23.7±1.5 and PLA, 28.9±1.5; F(1, 180.4)=5.98, p=0.02) and slightly reduced the S-VAS score (BACL, 5.04±0.24 and PLA, 5.70±0.25; F(1, 170.0)=3.60, p=0.059).2”
InfluentialVangeli, E., Stapleton, J., Smit, E. S., Borland, R., & West, R. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03565.x · Cited by 607 · cited 2×
“This finding is consistent with the strong predictive effects of nicotine dependence severity on cessation in smoking treatments in general (Vangeli et al. 2011).”
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461 · cited 2×
“At week 01 visit, eligible participants were randomized to BACL or PLA using a 3-urn variable procedure (Stout et al. 1994), i.”
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 1×
“…made to identify possible treatments that could help patients with alcohol and nicotine co-dependence, e.g., varenicline (Jimenez-Ruiz et al. 2009; Litten et al. 2013), naltrexone (Fucito et al. 2012), topiramate (Baltieri et al. 2009; Johnson et al. 2005), and combined nicotine patch and gum…”
The COMBINE Study Research Group (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb02873.x · Cited by 174
Cited by
Lee, M. R., Tapocik, J. D., Ghareeb, M., Schwandt, M. L., Dias, A. A., Le, A. N., Cobbina, E., Farinelli, L. A., Bouhlal, S., Farokhnia, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0064-y · Cited by 129
Self-citationThe Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Self-citationBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68
Metadata
- Authors
- Leggio, L., Zywiak, W. H., Edwards, S. M., Tidey, J. W., Swift, R. M., & Kenna, G. A.
- Venue
- Psychopharmacology
- Published
- 2014-06-29
- Volume
- 232
- Issue
- 1
- Pages
- 233-243
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2035839366
- Cited by
- 46
- References
- 7
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. https://app.cochat.ai/papers/10.1007/s00213-014-3652-9
- The paper
- Leggio, L., Zywiak, W. H., Edwards, S. M., Tidey, J. W., Swift, R. M., & Kenna, G. A. (2015). A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology. https://doi.org/10.1007/s00213-014-3652-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.